In innate immune resistance, oncogenic gene alterations in NSCLC, such as EGFR mutations [17, 18], ALK rearrangements [19], and PTEN loss followed by the activation of the PI3K–Akt pathway [20], induce PD-L1 expression leading to the inhibition of tumor cell destruction by immune cells. The gene discussed is EGFR; the disease is neoplasm.